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Abstract
Background: Coronary heart disease (CHD) mortality rates have been decreasing in Iceland since the 1980s, largely
reflecting improvements in cardiovascular risk factors. The purpose of this study was to predict future CHD mortality in
Iceland based on potential risk factor trends.
Methods and findings: The previously validated IMPACT model was used to predict changes in CHD mortality between
2010 and 2040 among the projected population of Iceland aged 25–74. Calculations were based on combining: i) data on
population numbers and projections (Statistics Iceland), ii) population risk factor levels and projections (Refine Reykjavik
study), and iii) effectiveness of specific risk factor reductions (published meta-analyses). Projections for three contrasting
scenarios were compared: 1) If the historical risk factor trends of past 30 years were to continue, the declining death rates of
past decades would level off, reflecting population ageing. 2) If recent trends in risk factors (past 5 years) continue, this
would result in a death rate increasing from 49 to 70 per 100,000. This would reflect a recent plateau in previously falling
cholesterol levels and recent rapid increases in obesity and diabetes prevalence. 3) Assuming that in 2040 the entire
population enjoys optimal risk factor levels observed in low risk cohorts, this would prevent almost all premature CHD
deaths before 2040.
Conclusions: The potential increase in CHD deaths with recent trends in risk factor levels is alarming both for Iceland and
probably for comparable Western populations. However, our results show considerable room for reducing CHD mortality.
Achieving the best case scenario could eradicate premature CHD deaths by 2040. Public health policy interventions based
on these predictions may provide a cost effective means of reducing CHD mortality in the future.
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Introduction
In most industrialized countries coronary heart disease (CHD)
death rates have declined considerably during the past two to three
decades [1]. However, there is evidence that this mortality decline
is levelling off, particularly among young adults, for example in
USA, Australia, England and Wales [2–4]. Furthermore, world-
wide, CHD remains the most common cause of death [5]. It is
therefore important to focus on the future and try to predict CHD
death trends in the next few decades. Over 90% of all cases of
myocardial infarction are attributable to a few well known and
modifiable risk factors [6]. The main reason for the stalling decline
in death rate is adverse trends in some of these established risk
factors. In most Western countries, diabetes and obesity have been
increasing rapidly, especially among young people [7–9]. In some
countries adverse trends in other risk factors have also been
causing concern, including blood pressure rises among men and
persistent smoking among women in the USA [7]. These
unfavourable trends might reverse the recent decline in CHD
mortality rates.
Ageing of the population increases the lifetime exposure to the
risk factors and further threatens the positive mortality trends. This
could increase the actual burden of CHD [3]. When predicting
future CHD mortality, it is therefore necessary to account for both
the ageing population and possible risk factor trends in the coming
decades.
In Iceland, there is easy access to reliable data including a large
unselected epidemiologic database, the Reykjavik study [10]. In
the present study we therefore applied the IMPACT model to the
Icelandic population. The IMPACT model has proven its value in
linking population risk factor changes to trends in CHD death
rates in diverse populations (including England, Ireland, Scotland,
Finland, USA, China, New Zealand, Sweden, Poland, the Czech
Republic and Iceland), including validation against the actual
change in mortality rates observed in these countries [10–21]. An
analysis comparing estimated mortality falls according to the
Icelandic IMPACT model and observed mortality falls in 1981–
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85800
2006 showed a reasonably good fit [10]. Subsequently, the model
has been used to estimate the potential for preventing future CHD
deaths by increasing uptake of appropriate treatments or by
reductions in specific risk factors in the population [22–24].
The purpose of this study was therefore to predict future CHD
mortality in Iceland based on potential trends in risk factor levels.
We present three distinct scenarios for risk factor changes over the
next thirty years and calculate the consequent trends in CHD
mortality for each. Predictions of future development in CHD
death rates in Iceland may prove relevant for other Western
populations, given the fact that cardiovascular risk factors have
similar or even identical effects on the pathogenesis of cardiovas-
cular diseases in Iceland as in other Western countries and the very
similar impact of specific risk factor trends on cardiovascular death
rates [10–18,25]. Furthermore, very similar risk factor impact has
been demonstrated in the Eastern European countries of Poland
and the Czech Republic, though trends in CHD mortality decline
are delayed compared to Western Europe [20–21]. Public health
policy interventions based on these predictions may provide a cost
effective means of reducing CHD mortality in the years to come.
Methods
The Reykjavı´k Study
For the past decades, the Icelandic Heart Association (IHA) has
conducted prospective population based cardiovascular surveys,
the Reykjavik study and The REFINE Reykjavik study. These are
unselected databases representing a large proportion of the general
population and they examine conventional cardiovascular risk
factors. The design of these studies has been described in detail in
previous reports [10].
Ethical Statement
The REFINE Reykjavik Study was approved by the National
Bioethics Committee and all participants gave written informed
consent for participation.
The IMPACT CHD Model
The IMPACT model was designed to explain changes in CHD
mortality rates in a population from changes in established risk
factors. It calculates how many premature deaths, defined as
deaths before the age of 75, would be prevented or postponed
because of a certain change in population risk factor level or
treatment uptake. The model has been used previously to analyze
the decline in CHD mortality rates in Iceland over the years 1981–
2006 [10]. In this study, the focus was on risk factor changes
exclusively and their specific impact on CHD mortality. Instead of
analyzing observed mortality falls in the past we extended the
previously calibrated Iceland IMPACT model to the future, in
order to predict CHD mortality in different situations. We used
three contrasting risk factor development scenarios to calculate
deaths prevented or postponed (DPPs) in the Icelandic population
aged 25–74 from 2010 to 2020, 2030 and 2040 respectively.
The models calculations of DPPs from risk factor changes are
based on combining the following three sets of variables:
a. Expected number of deaths in the final year: Calculated by
applying the age specific CHD death rate of 2010 to the
expected population in the final year, by sex and 10-year age
groups from age 25–74.
b. Changes in population levels and prevalence of major
cardiovascular risk factors: Smoking: self-reported current
smoking, Systolic blood pressure (systolic BP): measured,
mmHg, Cholesterol: measured fasting cholesterol, mmol/l,
Physical inactivity: self-reported, defined as ‘‘not currently
exercising regularly’’, Body mass index (BMI): measured, kg/
m2.
Diabetes: defined as self-reported history of diabetes, measured
elevated fasting glucose or medication use.
c. Effectiveness of specific risk factor changes on CHD mortality
based on published meta-analyses. The model employs
regression coefficients or relative risk values obtained from
multivariate logistic regression analyses. Each coefficient
quantifies the independent log linear relationship between
the absolute change in a specific cardiovascular risk factor and
the consequent change in the number of CHD deaths in the
population.
Data sources are summarized in table 1.
Risk Factor Scenarios
Three future risk factor scenarios were designed. They were
meant to represent contrasting but feasible possibilities in risk
factor development that could be used to calculate possible trends
in CHD mortality. The first scenario was based on historical risk
factor trends (past 30 years) continuing, the second scenario was
based on recent risk factor trends (past five years) continuing, and
the third scenario assumed that in 2040 the entire population
would enjoy optimal risk factor levels observed in low risk cohorts
as defined by Stamler et al and Daviglus et al [26–27]. Table 2
provides a comparison of the scenarios. Finally, these three
different risk factor scenarios were used to design a fourth scenario,
a proposal for obtainable risk factor goals, using the risk factor
changes considered to be most effective and realistic.
Methodological and Statistical Considerations
Calculations in the IMPACT model were made separately for
men and women in 10 year age groups to account for potential
differences in effect. Since all the beta coefficients and relative risk
values were obtained from multi-variable models they were
assumed to be independent. Therefore the DPPs from each risk
factor change could be summed. Finally, the total number of
CHD-deaths in the final year (2040) was calculated by subtracting
the DPPs in that year from the number of deaths expected if 2010
death rates persisted unchanged. The final results were then
presented as deaths per 100,000 population.
In this study, calculations included risk factor changes only, not
treatments. For example the role of anti-hypertensive and
hypercholesterolemia treatments in changes in blood pressure
and cholesterol levels were not accounted for. The calculations
were based on overall changes in these risk factors, regardless of
how they were achieved. It has in fact been demonstrated that
changes in total cholesterol levels in Western societies, including
Iceland, are not related to statin, but rather dietary factors [28].
Because of the uncertainties surrounding many of the values,
multi-way sensitivity analyses were performed using Briggs analysis
of extremes method.
Further details on the methods and data sources used in this
study, as well as examples of the calculations used in the model are
provided in Appendix S1.
Results
If no changes in CHD risk factor levels occurred among the
Icelandic population over the coming decades, the same age
specific death rates recorded in 2010 would be expected to persist
in 2040. This would result in the number of CHD deaths among
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people aged 25–74 years increasing from approximately 49 to
68 per 100,000 (Table 3), simply reflecting population ageing.
Observed risk factor values in 1981, 2006 and 2010 are
summarized in table 4, along with information on the sample sizes
and gender and age distribution from the Reykjavik study and
REFINE Reykjavik study. Risk factor values in each of the future
scenarios are summarized in table 5.
If Historical Trends Continued
The impact of each risk factor change in each scenario is
summarized in table 5. If historical trends continued, the beneficial
development in mean systolic BP, cholesterol level, and the
prevalence of smoking and physical inactivity would result in
approximately 30 deaths prevented or postponed (DPPs) per
100,000 in the year 2040. On the other hand, mean BMI would be
expected to rise to 30?3 kg/m2 and diabetes prevalence would
reach 7?5% in 2040, together causing 5 additional deaths per
100,000. The overall outcome would therefore be to decrease the
number of deaths in 2040 by 25 per 100,000, a 37% reduction
compared to the 68 deaths per 100,000 expected with no risk
factor change (Table 5).
If Recent Trends Continued
Continuing recent risk factor trends of past five years would
result in the unfavourable risk factor changes outweighing the
benefits of favourable risk factor changes causing a slightly higher
death rate compared to no risk factor changes occurring, a total of
3 deaths per 100,000 added (Table 5).
Low Risk Scenario
Finally, if the ideal scenario was achieved and the entire
population could enjoy the optimal risk factor levels observed in
low risk individuals, a total of approximately 71 deaths per
100,000 would be prevented or postponed in the year 2040. The
greatest contributions would result from lowering systolic blood
pressure (34%), smoking prevalence (19%) and cholesterol level
(17%). Reaching optimal diabetes prevalence and mean BMI
would together reduce deaths by 12 per 100,000 in 2040 (Table 5).
We explored the impact of minimum and maximum model
parameters using Briggs analysis of extremes method. According
to this sensitivity analysis, substantially changing the values
influenced the number of deaths prevented or postponed but did
not influence the relative contribution of each risk factor change in
each scenario (Table 5, columns 5 and 6).
Figure 1 demonstrates how mortality rates would develop from
2010 to 2040 in each risk factor scenario and compares them to
the baseline scenario if no risk factor changes were to occur. If the
historical risk factor trends were to continue, the declining death
rates of past decades would level off. This would be the case
despite 25 fewer deaths per 100,000 in 2040 (Table 5) and is
primarily explained by the population ageing. Nevertheless,
continuing historical trends would result in a lower death rate
(43 per 100,000) compared to no risk factor changes (68 per
100,000). Since the trends of past five years are less favourable and
result in additional deaths in 2040, continuing those recent trends
would result in a death rate increasing from 49 to 70 per 100,000
from 2010 to 2040. In contrast reaching optimal risk factor levels
would essentially eliminate all premature preventable CHD deaths
before 2040 (Figure 1).
Table 1. Data sources.
Data Source
CHD mortality in 2010 Statistics Iceland (mean mortality 2007–2009*)
Population projections 2020, 2030 and 2040 Statistics Iceland
Risk factor levels 1981 Reykjavik study (data from 1979–1983), n = 5391, mean age 53611
Risk factor levels 2006 REFINE Reykjavik study (data from 2005–2007), n = 4161, mean age 60613
Risk factor levels 2010 REFINE Reykjavik study (data from 2009–2011), n = 9552, mean age 52612
*CHD mortality in 2010 was not available.
doi:10.1371/journal.pone.0085800.t001
Table 2. Overview of three future risk factor scenarios.
Scenario Risk factor development
Historical trends continue: Assuming risk factor trends of
past 30 years (1981–2010) continued.
In this 30 year period there was considerable decline in CHD mortality, largely attributable
to favourable changes in population risk factor levels (cholesterol, systolic BP, smoking and
physical inactivity). However, BMI and diabetes prevalence rose steadily.
Recent trends continue: Assuming the recent risk factor trends of
past five years (2006–2010) continue.
In the past five years there was a relevant plateau in decreasing cholesterol level among
both sexes and systolic blood pressure in men stopped falling and has been increasing
since 2006. Systolic blood pressure in women has recently declined in a slower rate than
previously. Furthermore, the recent increase in BMI and diabetes has accelerated.
Low risk scenario: Assuming that the mean risk factor levels of
the whole population will progressively (35% by 2020, 65% by 2030,
and 100% by 2040) reach the optimal levels already reported in
low risk cohorts, as defined by Stamler et al and Daviglus
et al. [26–27]
This includes zero smoking, diabetes and physical inactivity. A systolic BP of 115 mmHg, a
total cholesterol of 4.5 mmol/l, and mean BMI of 24 kg/m2
doi:10.1371/journal.pone.0085800.t002
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Obtainable Goals
Figure 2 compares the potential effects of changes in each risk
factor on the number of deaths in each scenario. A new scenario
was made by combining the most effective and realistic risk factor
changes in the three different scenarios. These changes are
summarized in table 6. The net result of reaching these goals
would be to decrease the number of deaths in 2040 by
approximately 35 per 100,000 compared to no risk factor changes
occurring (Table 6). This would result in death rate decreasing
from 49 to 33 per 100,000 from 2010 to 2040 (Figure 3).
Discussion
Coronary heart disease death rates in Iceland decreased by 80%
during the 25 year period 1981–2006 [29]. This has greatly
increased life expectancy and lowered premature deaths. However
our results suggest that without significant population lifestyle
changes these mortality trends might plateau or even reverse in
coming decades. Even if the mostly favourable CHD risk factor
trends of the past 30 years were to continue to 2040, the declining
death rates of past decades would level off. This surprising result is
explained by continuing adverse trends in diabetes and BMI as
well as population ageing. Worse still, risk factor trends during the
last five years (2006–2010) are less positive than the three previous
decades and suggest an alarming trend. In addition to faster
increases in diabetes and obesity, cholesterol levels have plateaued
and men’s blood pressure is actually rising. If these recent trends
continue to 2040 we are facing a public health disaster, where
CHD mortality will increase and the gains of past decades will be
lost. However there is room for considerable improvement as
shown by the more optimistic scenario assuming that in 2040 the
Table 3. Population numbers and CHD deaths in Iceland in 2010, and expected population numbers and CHD deaths in 2040 if
2010 rates persist.
Population in
2010
Population in
2040
CHD deaths
2010
CHD death rate per
100.000 2010
CHD deaths in 2040 if
2010 rates persisted
CHD death rate per
100.000 2040
Men
25–34 23895 25912 0 1.4 0 1.4
35–44 21994 23744 2 10.1 2 10.1
45–54 21860 23975 11 49.4 12 49.4
55–64 16971 22918 22 128.8 30 128.8
65–74 9560 19593 40 419.3 82 419.3
Total 94280 116142 75 126
Women
25–34 22666 25012 0 0.0 0 0.0
35–44 21126 23428 0 1.6 0 1.6
45–54 21409 23097 0 1.6 0 1.6
55–64 16353 22505 3 17.5 4 17.5
65–74 10093 19749 13 124.9 25 124.9
Total 91647 113791 16 29
TOTAL 185927 229933 91 49 156 68
doi:10.1371/journal.pone.0085800.t003
Table 4. Data on sample characteristics and risk factor values from the Reykjavik study (1981) and REFINE Reykjavik study (2006
and 2010).
Year 1981 2006 2010
n 5391 4161 4326
Mean age (SD) 53 (11) 60 (13) 52 (12)
Males (%) 47 45 50
Men Women Men Women Men Women
Smoking prevalence (%) 50.8 42.3 23.1 22.1 21.5 19.7
Mean systolic bp (mmHg) 128.6 123.4 125.2 116.7 126.1 115.4
Mean blood cholesterol (mmol/l) 5.92 6.05 5.16 5.12 5.16 5.18
Physical inactivity prevalence (%) 77.8 74.4 54.7 52.9 47.9 43.3
Mean BMI (kg/m2) 25.4 24.5 27.5 26.5 28.0 26.8
Diabetes prevalence (%) 2.0 1.5 4.8 2.4 5.2 3.1
doi:10.1371/journal.pone.0085800.t004
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entire population enjoys risk factor levels currently observed in low
risk individuals.
Mortality and Risk Factor Development
The majority (74%) of the reduced mortality between 1981 and
2006 was explained by improvement in risk factors in the
community. A decrease in blood cholesterol, explained approxi-
mately 32% of the reduction, and cigarette smoking and systolic
BP, each explained some 22% of the reduction [10]. Adverse
Icelandic trends during the last five years cause great concern.
Unopposed, the recent plateau in cholesterol levels will cause a 3%
increase in deaths in 2040 and increasing blood pressure among
men may increase mortality by 10%. These adverse trends may
reflect a shift to a more unhealthy diet, following the financial crisis
in 2008. Furthermore, if recent rising trends in diabetes and
obesity continue, they will result in an 11% increase in deaths in
2040, echoing similar concerns in other Western countries,
including the USA [7]. It has been predicted by Olshansky and
colleagues that life expectancy in the United States could level off
or even decline within the first half of the 21st century as a result of
the substantial rise in the prevalence of obesity and it’s life-
shortening complications, such as diabetes [30]. Because of the
Table 5. CHD deaths per 100,000 prevented or added as a result of risk factor changes, under three cardiovascular risk factor
scenarios.
Risk factor scenario: Fewer/additional deaths per 100,000 in 2040
Risk factor value Both sexes Best estimate
Men Women Best estimate
Minimum
estimate
Maximum
estimate Men Women
Smoking prevalence (%)
In 2010 21.5% 19.7% – – – – –
Historical trends continue, 2040 8.5% 8.7% 27 26 28 26 21
Recent trends continue, 2040 13.3% 7.9% 25 24 26 23 21
Low risk scenario, 2040 0.0% 0.0% 213 211 216 211 22
Mean systolic blood pressure (mmHg)
In 2010 126.1 115.4 – – – – –
Historical trends continue, 2040 123.9 108.7 28 25 211 25 23
Recent trends continue, 2040 130.8 107.1 3 2 5 7 24
Low risk scenario, 2040 115.8 112.7 224 217 232 220 24
Mean blood cholesterol (mmol/l)
In 2010 5.16 5.18 – – – – –
Historical trends continue, 2040 4.45 4.44 212 29 216 210 23
Recent trends continue, 2040 5.19 5.65 2 1 3 1 2
Low risk scenario, 2040 4.48 4.48 212 28 216 29 23
Physical inactivity prevalence (%)
In 2010 47.9% 43.3% – – – – –
Historical trends continue, 2040 29.1% 24.9% 23 23 24 23 21
Recent trends continue, 2040 18.2% 9.6% 25 24 27 24 21
Low risk scenario, 2040 0.0% 0.0% 29 27 210 27 22
Mean BMI (kg/m2)
In 2010 28.0 26.8 – – – – –
Historical trends continue, 2040 31.1 29.5 4 2 6 3 1
Recent trends continue, 2040 32.7 29.4 6 3 9 5 1
Low risk scenario, 2040 25.3 23.0 24 22 26 23 21
Diabetes prevalence (%)
In 2010 5.2% 3.1% – – – – –
Historical trends continue, 2040 9.5% 5.3% 2 1 2 1 0
Recent trends continue, 2040 8.7% 8.6% 2 1 2 1 1
Low risk scenario, 2040 0.0% 0.0% 28 26 29 26 22
Totals
Historical trends continue, 2040 – – 225 218 232 218 27
Recent trends continue, 2040 – – 3 21 7 6 23
Low risk scenario, 2040 – – 271 251 290 256 214
May not sum to total due to rounding.
doi:10.1371/journal.pone.0085800.t005
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transferability of the results, the possibly disastrous future
development in CHD death rates is alarming both for Iceland
and for the majority of Western populations.
Preventing Premature Deaths in the Future
Despite a pessimistic view of the future, our results also show
considerable room for improvement. The scenarios are not equally
realistic. For example, according to the low risk scenario, men‘s
mean systolic blood pressure will reach 115?8 mmHg in 2040,
perhaps an unrealistic and not very effective goal. In fact assuming
that the entire population obtains a low risk profile is a highly
unrealistic scenario especially in light of recent concerning risk
factor trends in Iceland. Furthermore, the total outcome of this
scenario would be to eliminate all premature CHD deaths before
2040. This would be the result of risk factor changes only, despite
the fact that 25% of the mortality decline in Iceland the past
(1981–2006) has been attributed to treatment effects [10].
However, it can be argued that treatment uptake is dependent
on risk factor levels and disease prevalence so that lowering risk
factor values would decrease the overall importance of treatment
interventions. Furthermore, the purpose of presenting the low risk
scenario was not to put forward a realistic future vision where the
low risk factor goals would be achieved in all age and sex groups
but rather to use the calculations to demonstrate which risk factor
changes are most effective and realistic. They where then used to
construct a fourth scenario based on the most efficient and realistic
risk factor changes from the other scenarios. This is in line with the
targets put forward by the World Health Organization for
prevention and control of non-communicable diseases [31]. The
dramatic net result of reaching these obtainable goals would be
halving the expected death rates in 2040, from 68 per 100.000 to
33 per 100.000. This eloquently demonstrates that further
reductions in CHD mortality are possible, despite the population
ageing, even when mortality rates approach zero and further
mortality decreases become harder to achieve.
In order to achieve these new goals we need to commit to a
multi sectored effort involving various institutions and govern-
mental interventions. In general, the most effective approach to
cardiovascular disease prevention is risk factor reduction in
apparently healthy people (population based prevention) rather
than in individuals at high risk of future CHD events [32]. The
focus must therefore be on tobacco control, healthy diet and
exercise. It is important to start early and provide children with
healthy school meals and physical education. In order to secure
continuing drops in smoking rates, it is important to further tighten
the legislation and invest in preventive measures, including plain
packaging and licensing of retail outlets. Food products must be
priced according to their wholesomeness and healthy food should
be made more visible and accessible. A recently approved
regulation that limits the amount of trans fats in foods to two
grams per 100 grams will hopefully have a positive effect on
cholesterol values in the future. Similar laws have existed in
Denmark for several years with very good results [33].
Strengths and Limitations of this Study
Modelling studies have a number of strengths. They offer the
potential to further our understanding of coronary heart disease
epidemiology and can transparently consider and simultaneously
integrate large amounts of data from many sources. Nevertheless
they can be considered a crude simplification of a complex reality
and there are many assumptions involved in this approach. One
for example is to apply results from primary research studies to
different populations and assuming that concomitant risk factor
reductions are independent. Explicit assumptions can however be
tested by sensitivity analysis as is done here [34]. Furthermore, the
long tradition of high quality national population surveys and
registries in Iceland reduces the potential problem of needing to
make assumptions about dubious data. This study focuses on
future CHD mortality, thus implying more uncertainties com-
pared to studying the past. As an example, here we only consider
the effects of risk factor changes and assume that the effect of
treatment will remain unchanged. We therefore assume that even
future advances in treatment would not substantially reduce the
importance of risk factor improvements and the subsequent gains.
Despite aforementioned concerns over increased burden of
CHD due to population ageing this study focuses on premature
deaths. This was done for several reasons. The original IMPACT
model includes only those adults aged 25–74 years old because of
very limited data in older groups [10]. Furthermore, the modelling
of deaths prevented or postponed becomes increasingly compli-
cated and unreliable with extremes in age due to comorbidity and
other complicating factors. However, changes in age composition
of people aged 25–74 is accounted for. Also, it can be argued that
risk factor changes among those under 75 years old will influence
the health and death rate among this group as it grows older.
Conclusions
If the mostly favourable CHD risk factor trends of the past 30
years in Iceland were to continue, the declining death rates of past
decades would level off, reflecting population ageing and
continuing rises in diabetes and BMI. The potential future
increase in mortality with recent adverse trends in risk factor
levels is alarming and potentially relevant to other Western
Figure 1. Future CHD mortality rate among 25–74 year old
Icelanders in three different risk factor scenarios.
doi:10.1371/journal.pone.0085800.g001
Figure 2. Estimated deaths per 100.000 prevented or added in
2040. Estimated deaths by risk factor change, under three risk factor
scenarios.
doi:10.1371/journal.pone.0085800.g002
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populations. However, our other scenarios offer considerable
room for reducing future CHD mortality, especially by evidence-
based population-wide preventive interventions. Achieving the
best case scenario could essentially eradicate premature CHD
deaths by 2040.
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